Figure 5.

Kaplan-Meier estimates of distant relapse-free survival in the discovery cohort (A–D) and the independent validation cohort (E–H) of patients treated with sequential taxane-anthracycline chemotherapy, then endocrine therapy if hormone receptor-positive, stratified by other signatures reported to be predictive of response to neoadjuvant taxane-anthracycline chemotherapy.^{9, 19, 30} A prognostic signature for genomic grade index predicts pathologic response if high GGI versus low GGI (A, E)¹⁹; the intrinsic subtype classifier predicts pathologic response if basal-like or luminal B versus other subtypes (B, F)³⁰; a genomic predictor of pathologic complete response (pCR) versus residual disease following taxane-anthracycline chemotherapy (C, G)⁹; and the genomic predictor of excellent pathologic response (pCR or RCB-I) versus other residual disease, according to ER status, that we incorporated in the last step of our prediction algorithm (D, H).^{9, 19, 30} P-values are from the log-rank test.